CD22 and myeloid neoplasm: The WHO 2016 updated classification of hematological malignancies of myeloid neoplasms and acute leukemia has defined the criteria for assignment of the B-ALL lineage by FC on the basis of the intensity of expression of four key markers: CD19, CD79a, cytoplasmic CD22, and CD10 [10, 11].